Email this article Role of antithymocyte globulin in reducing the incidence of complications after allogeneic hemopoietic cell transplantation
- Authors: Zalyalov Y.R1, Ganapiyev AA1, Golubovskaya IK1, Afanasyev BV2
-
Affiliations:
- Acad. I. P. Pavlov Saint Petersburg State Medical University
- Acad. I. P. Pavlov Saint Petersburg State Medical UniversityR. M. Gorbacheva Institute of Pediatric Hematology and Transplantology
- Issue: Vol 82, No 8 (2010)
- Pages: 53-56
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30648
- ID: 30648
Cite item
Full Text
Abstract
Subjects and methods. The study assessed the results of 92 allo-HCTs depending on the presence or absence of ATG in conditioning modes, the doses of Atgam (60 mg/kg or more), the presence or absence of acute leukemia (AL) in remission before HCT.
Results. In patients with AL in remission receiving ATG in conditioning modes (Atgam 60 mg/kg or thymoglobulin 7.5 mg/kg), overall three-year survival was 60%. Increasing the dose of Atgam up to more than 60 mg/kg resulted in higher transplantation-associated mortality (TAM) rates than did with the Atgam dose of 60 mg/kg (p < 0.01).
Conclusion. Allo-HCT is the treatment of choice for patients with AL in the presence of an HLA-identical related or unrelated donor. The use of Atgam in a course dose of not more than 60 mg/kg or thymoglobulin 7.5 mg/kg in conditioning modes is associated with low TAM rates and higher overall survival in earlier-stage disease in complete clinical hematological remission as compared with those in patients with expanded-stage AL, rather than in AL in remission at the start of conditioning before HCT.
About the authors
Yu R Zalyalov
Acad. I. P. Pavlov Saint Petersburg State Medical UniversityКафедра гематологии, трансфузиологии и трансплантологииаспирант; Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова; Acad. I. P. Pavlov Saint Petersburg State Medical University
A A Ganapiyev
Acad. I. P. Pavlov Saint Petersburg State Medical UniversityКафедра гематологии, трансфузиологии и трансплантологиид-р мед. наук, проф; Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова; Acad. I. P. Pavlov Saint Petersburg State Medical University
I K Golubovskaya
Acad. I. P. Pavlov Saint Petersburg State Medical UniversityКафедра гематологии, трансфузиологии и трансплантологииаспирант; Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова; Acad. I. P. Pavlov Saint Petersburg State Medical University
B V Afanasyev
Acad. I. P. Pavlov Saint Petersburg State Medical UniversityR. M. Gorbacheva Institute of Pediatric Hematology and TransplantologyКафедра гематологии, трансфузиологии и трансплантологиид-р мед. наук, проф., зав. каф; Санкт-Петербургский государственный медицинский университет им. акад. И. П. ПавловаИнститут детской гематологии и трансплантологии им. Р. М. Горбачевой; Acad. I. P. Pavlov Saint Petersburg State Medical UniversityR. M. Gorbacheva Institute of Pediatric Hematology and Transplantology
References
- . Remberger M. et al. Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant. 2002; 29: 391-397.
- Mohty M., Gaugler B. Inflammatory cytokines and dendritic cells in acute graft-versus-host disease after allogeneic stem cell transplantation. Cytokine Growth Factor Rev. 2008; 19 (1): 53-63.
- Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21 (7): 1387- 1394.
- Mohty M. Dendritic cells and acute graft-versus-host disease after allogeneic stem cell transplantation. Leukemia and Lymphoma 2007; 48 (9): 1696-1701.
- Zand M. S., Vo T., Huggins J. et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79 (11): 1507-1515.
- Naujokat C., Berges C., Fuchs D. et al. Antithymocyte globulins suppress dendritic cell function by multiple mechanisms. Transplantation 2007; 83 (4): 485-497.
- Bacigalupo A., Lamparelli T., Bruzzi P. et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001; 98 (10): 2942-2947.
- Mohty M., Bay J. O., Faucher C. et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regime. Blood 2003; 102 (2): 470-476.
- Storb R., Gluckman E. et al. Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood 1974; 44 (1): 1-10.
Supplementary files
